当前位置：
X-MOL 学术
›
Cancer Gene Ther.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Correction: ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis
Cancer Gene Therapy ( IF 4.8 ) Pub Date : 2020-11-09 , DOI: 10.1038/s41417-020-00250-z Katarzyna Bogucka , Federico Marini , Sebastian Rosigkeit , Janine Schloeder , Helmut Jonuleit , Kerstin David , Margarita Schlackow , Krishnaraj Rajalingam
Cancer Gene Therapy ( IF 4.8 ) Pub Date : 2020-11-09 , DOI: 10.1038/s41417-020-00250-z Katarzyna Bogucka , Federico Marini , Sebastian Rosigkeit , Janine Schloeder , Helmut Jonuleit , Kerstin David , Margarita Schlackow , Krishnaraj Rajalingam
An amendment to this paper has been published and can be accessed via a link at the top of the paper.
中文翻译：
更正：KRAS介导的NSCLC肿瘤发生需要ERK3 / MAPK6
该文件的修订版已经发布，可以通过文件顶部的链接进行访问。
更新日期：2020-11-12
中文翻译：
更正：KRAS介导的NSCLC肿瘤发生需要ERK3 / MAPK6
该文件的修订版已经发布，可以通过文件顶部的链接进行访问。
京公网安备 11010802027423号